Description
EO 14398 DEI DISCRIMINATION
Base award description: CU-64 DOTATATE RADIO-PHARMACEUTICAL
Modification chain · 13 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2022-02-28+$95,000= $95,000
- Mod P000012023-01-05+$95,000= $190,000
- Mod P000022023-10-26-$14,145= $175,855
- Mod P000032023-11-07+$97,200= $273,055
- Mod P000042023-11-09+$0= $273,055
- Mod P000052024-05-30-$4,690= $268,365
- Mod P000062024-10-15+$101,250= $369,615
- Mod P000072024-11-14+$97,200= $466,815
- Mod P000082025-05-01-$52,650= $414,165
- Mod P000092025-09-23+$101,250= $515,415
- Mod P000102025-11-13+$198,450= $713,865
- Mod P000112026-06-16+$0= $713,865
- Mod P000122026-07-16-$32,400= $681,465
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2022-02-28 | +$95,000 | $95,000 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00001· EXERCISE AN OPTION | 2023-01-05 | +$95,000 | $190,000 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00002· FUNDING ONLY ACTION | 2023-10-26 | −$14,145 | $175,855 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00003· EXERCISE AN OPTION | 2023-11-07 | +$97,200 | $273,055 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00004· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2023-11-09 | +$0 | $273,055 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00005· OTHER ADMINISTRATIVE ACTION | 2024-05-30 | −$4,690 | $268,365 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00006· OTHER ADMINISTRATIVE ACTION | 2024-10-15 | +$101,250 | $369,615 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00007· EXERCISE AN OPTION | 2024-11-14 | +$97,200 | $466,815 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00008· OTHER ADMINISTRATIVE ACTION | 2025-05-01 | −$52,650 | $414,165 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00009· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2025-09-23 | +$101,250 | $515,415 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00010· EXERCISE AN OPTION | 2025-11-13 | +$198,450 | $713,865 | CU-64 DOTATATE RADIO-PHARMACEUTICAL |
| Mod P00011· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-06-16 | +$0 | $713,865 | EO 14398 DEI DISCRIMINATION |
| Mod P00012· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-07-16 | −$32,400 | $681,465 | EO 14398 DEI DISCRIMINATION |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI EQ4VSLH8RC33)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24826N0411 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $231,773 | FY2026 |
| 36C24126N0274 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6505 · DRUGS AND BIOLOGICALS | $771,411 | FY2026 |
| 36C25226N0210 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $164,999 | FY2026 |
| 36C26126N0065 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $153,991 | FY2026 |
| 36C24825N0208 | 248-NETWORK CONTRACT OFFICE 8 (36C248) · 6505 · DRUGS AND BIOLOGICALS | $224,563 | FY2025 |
| 36C24125N0495 | 241-NETWORK CONTRACT OFFICE 01 (36C241) · 6505 · DRUGS AND BIOLOGICALS | $656,883 | FY2025 |
Other recipients under 6505 from 247-NETWORK CONTRACT OFFICE 7 (36C247) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24726P0690 | SINA DRUG LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $188,463 | FY2026 |
| 36C24726N0211 | BOSTON SCIENTIFIC CORP | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $248,982 | FY2026 |
| 36C24726F0100 | AMICUS THERAPEUTICS US, LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $228,396 | FY2026 |
| 36C24726F0053 | EXELAN PHARMACEUTICALS INC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $4,765,853 | FY2026 |
| 36C24726F0043 | AMICUS THERAPEUTICS US, LLC | 247-NETWORK CONTRACT OFFICE 7 (36C247) | $109,456 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24722P0498_3600_-NONE-_-NONE- · retrieved 2026-09-26.